NVO
Novo Nordisk A/SThesis. NVO trades at 11.9x trailing and 0.67x sales, a valuation that already prices in the sentiment collapse from the $71.80 high while Q1 2026 delivered +22% sequential revenue and a +23% EPS beat. Oral Wegovy and the obesity TAM expansion give a credible re-rating path, but negative FCF, a hold-heavy analyst base, and intensifying Lilly competition cap conviction short of an outright BUY.
Scoreboard
NVO trades at $49.64 against a $219.6B market cap and $345.3B enterprise value, sitting just 39.6% up its $35.12–$71.80 52-week band and still -30.9% below the high. The stock has clawed back 41% off the low and now holds above both its 50-day ($44.90) and 200-day ($47.75) averages. The $47.98 consensus mean target implies -3.3% downside, but that figure is stale — the $63.05 high target and the recent oral-Wegovy re-rating point to upside the mean has not yet repriced.
QoQ Changes
Q1 2026 revenue hit DKK 96.82B, up 22.3% QoQ from DKK 79.14B, with basic EPS of 10.93 nearly doubling the prior quarter's 6.06. Net income surged to DKK 48.56B from DKK 26.89B (+80.6% QoQ), and the quarter beat consensus EPS by 23.1%.
Margins snapped back hard: Q1 gross profit of DKK 83.23B implies an ~86% gross margin and operating income of DKK 59.62B a ~61.6% operating margin, versus a depressed 40% operating margin in Q4 2025. Trailing profitability remains elite — 83.2% gross, 61.6% operating, 53.0% EBITDA margin.
FCF is the blemish: FCF margin is -3.7% and FCF yield -5.5%, reflecting heavy capacity capex and dealmaking to feed incretin demand. Reported earnings quality is pristine, but cash conversion lags materially and warrants monitoring.
Total cash of DKK 21.63B is dwarfed by DKK 146.38B of debt, leaving a net debt position of roughly DKK 124.8B. Liquidity is tight — current ratio 0.79, quick ratio 0.54 — though comfortably serviceable against 53% EBITDA margins and 71% ROE.
At 11.9x trailing and 15.3x forward earnings, 0.67x sales and 1.05x EV/revenue, NVO trades at a steep discount to Eli Lilly and to its own multi-year history. PEG of 3.63 flags that the multiple compression already discounts a growth deceleration; P/B of 7.1x reflects the capital-light, high-return model.
NVO signed a non-exclusive agreement to evaluate Vivani's NPM-139 semaglutide implant (NanoPortal platform), extending the franchise toward long-duration dosing. Beyond this and the oral Wegovy ramp, the data provide no headcount, M&A, or restructuring detail.
Ownership & Insider Activity
Reported US institutional ownership is just 9.9% and insider holding a token 0.005% — both artifacts of the NYQ ADR line, since the bulk of the register and the controlling Novo Holdings stake sit on the Copenhagen listing. Short interest is benign at 0.77% of float (1.84 days to cover), though shares short rose to 24.5M from 21.7M a month prior — a modest uptick in bearish positioning. Finnhub SEC Form 4 data shows zero insider transactions in the window, so there is no directional insider signal to read.
Recent Insider Transactions
No recent insider transactions on file.
Earnings Quality
| Period | Actual EPS | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
| 2026-03-31 Q1 | $6.63 | $5.39 | +$1.24 | +23.06% |
| 2025-12-31 Q4 | $6.04 | $5.96 | +$0.08 | +1.39% |
| 2025-09-30 Q3 | $4.50 | $4.84 | $-0.34 | -7.04% |
| 2025-06-30 Q2 | $5.96 | $6.03 | $-0.07 | -1.15% |
NVO beat consensus in 2 of the last 4 quarters for a 50% beat rate and a +4.1% average surprise — a mixed record skewed entirely by the Q1 2026 +23.1% blowout that followed two prior misses.
The trajectory inflected sharply upward: after a -7.0% miss (Q3 2025) and -1.1% (Q2 2025), surprises swung to +1.4% then +23.1%, suggesting analysts were badly under-calibrated to the oral-Wegovy volume ramp and guidance now has room to be reset higher.
Analyst Action
| Month | Distribution | Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|---|---|
| 2026-07 | 5 | 8 | 22 | 1 | 1 | |
| 2026-06 | 5 | 7 | 23 | 1 | 1 | |
| 2026-05 | 5 | 7 | 23 | 1 | 1 | |
| 2026-04 | 5 | 7 | 23 | 1 | 1 |
The Finnhub rating series is remarkably static — 22-23 Holds dominate versus 13 combined Strong Buy/Buy and 2 sells across April–July 2026, with the only shift a one-notch migration from Hold to Buy in July (buy 7→8, hold 23→22).
Momentum is neutral-to-marginally-bullish: the analyst community remains parked on the sidelines and has yet to chase the recovering price.
Seven Essential Metrics
83.2% gross, 61.6% operating and 53.0% EBITDA margins with a 71.4% ROE and 19.2% ROA — best-in-class pharma economics.
Revenue +24% YoY and earnings +67.1% YoY, with Q1 net income up 80.6% sequentially.
FCF margin of -3.7% and FCF yield of -5.5% as capex and dealmaking outrun operating cash — the clear soft spot.
Net debt of ~DKK 124.8B against DKK 21.6B cash, but easily carried on 53% EBITDA margins; current ratio a thin 0.79.
Beta of just 0.36 and a fortress-margin, blockbuster-driven model keep bankruptcy risk negligible despite headline volatility.
11.9x trailing / 15.3x forward P/E and 0.67x sales — a wide discount to Lilly and to NVO's own history.
Structurally buyback-and-dividend friendly with 71% ROE; no dilution signal in the data.
NVO pays a semi-annual dividend and is cited among high-yield picks, but the yield is not provided in the data (n/a).
Competitive Snapshot
| Company | EBITDA Margin | 3Y Rev CAGR | FCF Margin | Leverage | Fwd P/E |
|---|---|---|---|---|---|
LLY Eli Lilly and Company | ~50% | ~35% | ~13% | ~1.5x net debt | ~28x |
AZN AstraZeneca PLC | ~35% | ~12% | ~18% | ~1.5x | ~16x |
AMGN Amgen Inc. | ~48% | ~10% | ~28% | ~3x | ~14x |
RHHBY Roche Holding AG | ~38% | ~3% | ~20% | <1x | ~14x |
NVO's 83% gross and 61% operating margins and 71% ROE top the peer set, yet at 15.3x forward it trades roughly half Lilly's multiple — a discount that reflects Lilly's superior growth trajectory and pipeline lead rather than NVO's own quality. Against diversified large-caps (AZN, AMGN, Roche), NVO offers markedly faster growth at a comparable or richer multiple, making it a relative-value play only versus Lilly, not the broader group.
Business & Strategy
Revenue splits across two segments — Obesity & Diabetes Care (the dominant engine, spanning Ozempic, Wegovy, and the newly launched oral Wegovy) and Rare Disease (rare blood/endocrine disorders, HRT). The mix is shifting decisively toward obesity as GLP-1 volumes and the oral franchise scale.
End demand flows through payers, national health systems, pharmacies, and physicians across Europe, North America, Japan, China, and emerging markets.
Overwhelmingly branded pharmaceutical product sales led by the semaglutide franchise, supplemented by insulin, devices (NovoPen), and rare-disease therapies. Recurring chronic-therapy prescriptions underpin visibility.
Manufacturing capacity build-out (fill-finish and API for injectables/orals), R&D, and intensifying commercial/SG&A spend to defend share against Lilly.
The moat is a deep GLP-1/incretin IP and manufacturing base plus decades of injectable-device and insulin expertise that newcomers cannot replicate quickly. That moat is real but narrowing as Lilly's tirzepatide and oral orforglipron erode NVO's first-mover advantage.
Monetary-Policy Sensitivity
- Long-duration growth equity — lower discount rate lifts terminal value
- Low beta (0.36) mutes broad-market beta capture
- Defensive healthcare demand largely rate-insensitive at the fundamental level
As a low-beta, long-duration compounder, NVO benefits modestly from a lower discount rate, but its 0.36 beta caps the multiple expansion relative to higher-beta growth names. Fundamentals — script volumes and reimbursement — are essentially rate-agnostic, so any uplift is valuation-driven rather than earnings-driven.
SWOT Analysis
- Elite margins (83% gross, 61% operating) and 71% ROE
- Dominant, entrenched GLP-1/incretin franchise with global reach
- Cheap valuation at 11.9x trailing / 0.67x sales
- Re-accelerating earnings — +67% YoY, +23% Q1 EPS beat
- Negative free cash flow (-3.7% margin, -5.5% yield)
- Tight liquidity — current ratio 0.79, quick 0.54
- Net debt of ~DKK 125B
- Hold-heavy analyst base with mean target below spot
- Oral Wegovy expanding the addressable obesity market
- Long-duration semaglutide implant (Vivani NPM-139)
- Emerging-market and cardiovascular/MASH indication expansion
- Multiple re-rating back toward historical norms
- Eli Lilly's tirzepatide and oral orforglipron taking share
- Pricing/reimbursement pressure and US drug-cost politics (TrumpRx)
- Margin compression from competitive discounting
- Waves of new GLP-1 entrants flagged by Reuters
Catalysts & Event Risks
- Q3 2026Q2 2026 earnings
Next print tests whether the Q1 volume acceleration and margin recovery are durable or a one-quarter snap-back.
- Q3 2026Oral Wegovy sales trajectory
Prescription and revenue data on the oral GLP-1 launch is the single biggest driver of the re-rating thesis.
- Q4 20262026 guidance revision
Management's willingness to raise full-year guidance after a +23% beat would recalibrate the depressed consensus.
- 2026Vivani NPM-139 implant evaluation
Progress on the semaglutide implant could open a differentiated long-duration dosing pathway.
- Q3 2026Competitive readouts (Lilly, Altimmune)
Rival Phase 3 data (orforglipron, pemvidutide) will reprice NVO's relative pipeline positioning.
The near-term setup hinges on oral Wegovy sell-through and a guidance raise — both plausible after the Q1 beat — while competitive readouts remain the primary downside risk. Catalyst skew is favorable but two-sided.
Technical Analysis
NVO has reclaimed both its 50-day ($44.90) and 200-day ($47.75) moving averages, printing a golden-cross-adjacent structure that reads as accumulation after a brutal -31% drawdown from the high. Price sits at the 40th percentile of its 52-week range, leaving asymmetric room to the upside. First support is the 50-day at ~$44.90 with the $35.12 low as the disaster case; resistance clusters near $50.44 (day high) and then $55, with the $63 analyst high the stretch target. Risk-reward favors accumulating into the base rather than chasing breakouts.
Verdict
Macro context. The GLP-1/obesity market remains the highest-growth theme in large-cap pharma, but the backdrop is now defined by escalating NVO-vs-Lilly competition and US drug-pricing politics (Medicaid/CHIP cuts, TrumpRx) that pressure reimbursement and sentiment across the group.
NVO offers a rare combination for a mega-cap compounder: 24% revenue and 67% earnings growth, 71% ROE, and best-in-class margins, all available at 11.9x trailing and 0.67x sales after a 31% drawdown from the high. The offsets are real — negative free cash flow, tight liquidity, a Hold-anchored analyst base, and a resurgent Lilly narrowing the moat — which is why this is an ACCUMULATE, not a BUY. Build a position into the $45 support zone with a $55 target; the risk-reward is skewed favorably as long as oral Wegovy volumes confirm the Q1 inflection.
Data source: Yahoo Finance / yfinance · fetched 7/8/2026, 6:43:23 AM